Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China

Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China

Abstract Background Immune checkpoint inhibitors (ICIs) are the standard treatment for advanced lung cancer, but immune‐related adverse events (irAEs) remain poorly understood, especially in a real‐world setting. Methods A multicenter observational study was conducted. Medical records of lung cancer...

Full description

Bibliographic Details
Main Authors: Yuequan Shi, Jian Fang, Chengzhi Zhou, Anwen Liu, Yan Wang, Qingwei Meng, Cuimin Ding, Bin Ai, Yangchun Gu, Yu Yao, Hong Sun, Hui Guo, Cuiying Zhang, Xia Song, Junling Li, Bei Xu, Zhiqiang Han, Meijun Song, Tingyu Tang, Peifeng Chen, Hongmin Lu, Yongjie Shui, Guangyuan Lou, Dongming Zhang, Jia Liu, Xiaoyan Liu, Xiangning Liu, Xiaoxing Gao, Qing Zhou, Minjiang Chen, Jing Zhao, Wei Zhong, Yan Xu, Mengzhao Wang
Format: Article
Language:English
Published: Wiley 2022-02-01
Series:Thoracic Cancer
Subjects:
advanced lung cancer
immune checkpoint inhibitors
immune‐related adverse events
real‐world data
Online Access:https://doi.org/10.1111/1759-7714.14274

Internet

https://doi.org/10.1111/1759-7714.14274

Similar Items